We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+14.65%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$331M
AUM Growth
+$11.7M
Cap. Flow
-$13.4M
Cap. Flow %
-4.06%
Top 10 Hldgs %
42.42%
Holding
75
New
12
Increased
16
Reduced
23
Closed
21

Top Buys

1
NVO
Novo Nordisk
NVO
+$14.7M
2
BPMC
Blueprint Medicines
BPMC
+$9.93M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.99M
4
JANX icon
Janux Therapeutics
JANX
+$6.09M
5
DYN icon
Dyne Therapeutics
DYN
+$3.98M

Top Sells

1
BHVN icon
Biohaven
BHVN
+$19.1M
2
VRDN icon
Viridian Therapeutics
VRDN
+$8.38M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$8.04M
4
SLNO
Soleno Therapeutics
SLNO
+$7.18M
5
PCVX icon
Vaxcyte
PCVX
+$6.31M

Sector Composition

1 Healthcare 83.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
26
Replimune Group
REPL
$859M
$4.93M 1.49%
450,000
– –
CRBP icon
27
PUT
Corbus Pharmaceuticals
CRBP
$167M
$4.54M 1.37%
+220,000
New +$11.3M
BBIO icon
28
BridgeBio Pharma
BBIO
$15.9B
$4.46M 1.35%
175,000
+35,000
+25% +$919K
TSHA icon
29
Taysha Gene Therapies
TSHA
$1.71B
$4.32M 1.31%
2,150,000
+900,000
+72% +$1.97M
RYTM icon
30
Rhythm Pharmaceuticals
RYTM
$7.31B
$4.13M 1.25%
78,842
-38,546
-33% -$1.85M
ANNX icon
31
Annexon
ANNX
$950M
$3.85M 1.16%
650,000
+340,000
+110% +$2.02M
KRRO icon
32
Korro Bio
KRRO
$177M
$3.68M 1.11%
110,000
+10,000
+10% +$421K
INSM icon
33
CALL
Insmed
INSM
$23.5B
$3.65M 1.1%
50,000
-150,000
-75% -$11.1M
DYN icon
34
Dyne Therapeutics
DYN
$3.92B
$3.59M 1.09%
+100,000
New +$3.98M
ARVN icon
35
Arvinas
ARVN
$517M
$3.57M 1.08%
145,000
+70,000
+93% +$1.83M
CRBP icon
36
Corbus Pharmaceuticals
CRBP
$167M
$3.3M 1%
160,000
-15,000
-9% -$768K
BBOT
37
BridgeBio Oncology
BBOT
$686M
$3.13M 0.95%
300,000
– –
NUVB icon
38
Nuvation Bio
NUVB
$2.02B
$3.09M 0.93%
1,350,000
+200,000
+17% +$610K
SVRA icon
39
Savara
SVRA
$1.13B
$3.07M 0.93%
725,000
-325,876
-31% -$1.44M
TNYA icon
40
Tenaya Therapeutics
TNYA
$177M
$2.9M 0.87%
1,500,000
+150,000
+11% +$423K
RGNX icon
41
Regenxbio
RGNX
$511M
$2.78M 0.84%
265,000
+95,000
+56% +$1.16M
CRVS icon
42
Corvus Pharmaceuticals
CRVS
$1.25B
$2.64M 0.8%
+500,000
New +$1.8M
ABSI icon
43
Absci
ABSI
$1.4B
$2.1M 0.63%
+550,000
New +$2.19M
NGNE icon
44
Neurogene
NGNE
$744M
$2.1M 0.63%
50,000
-20,000
-29% -$776K
CAPR icon
45
Capricor Therapeutics
CAPR
$1.13B
$1.9M 0.57%
+125,000
New +$618K
APLS
46
DELISTED
Apellis Pharmaceuticals
APLS
$1.87M 0.57%
65,000
-70,000
-52% -$2.59M
SMMT icon
47
Summit Therapeutics
SMMT
$10.7B
$1.86M 0.56%
+85,000
New +$1.19M
SYRE icon
48
Spyre Therapeutics
SYRE
$8.7B
$1.76M 0.53%
60,000
-190,237
-76% -$5.3M
VRDN icon
49
Viridian Therapeutics
VRDN
$1.99B
$1.71M 0.52%
75,000
-512,708
-87% -$8.38M
PRQR icon
50
ProQR Therapeutics
PRQR
$240M
$1.62M 0.49%
887,700
-12,300
-1% -$23.1K
1
2
3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Ghost Tree Capital held 75 positions worth $331M, up 3.7% from $319M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ghost Tree Capital withdrew a net $13.4M in Q3 2024, closing 21 positions and reducing 23 holdings. Its most notable exit was Biohaven, an estimated $19.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 90% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Novo Nordisk worth $13.1M.

  • Ghost Tree Capital's largest Q3 2024 buy was Novo Nordisk: 110,000 shares worth $13.1M.
  • Ghost Tree Capital added most to Blueprint Medicines in Q3 2024, an estimated $9.93M increase.
  • Ghost Tree Capital's biggest Q3 2024 reduction was Viridian Therapeutics, cutting an estimated $8.38M.
  • Ghost Tree Capital fully exited Biohaven in Q3 2024, selling an estimated $19.1M.
  • Ghost Tree Capital's ten largest holdings make up 42% of its $331M portfolio in Q3 2024.
  • Ghost Tree Capital opened 12 new positions and closed 21 in Q3 2024.
  • Ghost Tree Capital's portfolio value rose 3.7% quarter-over-quarter to $331M.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.